The global clinical trial supplies market size accounted for USD 2.96 billion in 2024, grew to USD 3.15 billion in 2025 and is expected to be worth around USD 5.56 billion by 2034, registering a CAGR of 6.51% between 2024 and 2034. The North America clinical trial supplies market size is calculated at USD 1.63 billion in 2024 and is estimated to grow at a CAGR of 6.6% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trial Supplies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trial Supplies Market, by Phases, 2024-2034
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Clinical Trial Supplies Market, by Services, 2024-2034
9.1.1. Logistics & distribution
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Storage & Retention
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Supply Chain Management
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Packaging, labeling, and blinding
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Manufacturing
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Comparator sourcing
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. Clinical Trial Supplies Market, by End User, 2024-2034
10.1.1. Pharma & Biotech companies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Contract Research Organization (CRO)
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Medical Device Companies
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. Clinical Trial Supplies Market, by Therapeutic Area, 2024-2034
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. CNS & mental disorders
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Cardiovascular
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Digestive disorders
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Infectious diseases
11.1.5.1. Market Revenue and Forecast (2021-2034)
11.1.6. Metabolic disorders
11.1.6.1. Market Revenue and Forecast (2021-2034)
11.1.7. Immunology
11.1.7.1. Market Revenue and Forecast (2021-2034)
11.1.8. Blood disorders
11.1.8.1. Market Revenue and Forecast (2021-2034)
11.1.9. Other therapeutic areas (dermatological disorders, rare diseases, ENT diseases, Nephrology)
11.1.9.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Phases (2021-2034)
12.1.2. Market Revenue and Forecast, by Services (2021-2034)
12.1.3. Market Revenue and Forecast, by End User (2021-2034)
12.1.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Phases (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Services (2021-2034)
12.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Phases (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Services (2021-2034)
12.1.6.3. Market Revenue and Forecast, by End User (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Phases (2021-2034)
12.2.2. Market Revenue and Forecast, by Services (2021-2034)
12.2.3. Market Revenue and Forecast, by End User (2021-2034)
12.2.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Phases (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Services (2021-2034)
12.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Phases (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Services (2021-2034)
12.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Phases (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Services (2021-2034)
12.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Phases (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Services (2021-2034)
12.2.8.3. Market Revenue and Forecast, by End User (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Phases (2021-2034)
12.3.2. Market Revenue and Forecast, by Services (2021-2034)
12.3.3. Market Revenue and Forecast, by End User (2021-2034)
12.3.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Phases (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Services (2021-2034)
12.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Phases (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Services (2021-2034)
12.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Phases (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Services (2021-2034)
12.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Phases (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Services (2021-2034)
12.3.8.3. Market Revenue and Forecast, by End User (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Phases (2021-2034)
12.4.2. Market Revenue and Forecast, by Services (2021-2034)
12.4.3. Market Revenue and Forecast, by End User (2021-2034)
12.4.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Phases (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Services (2021-2034)
12.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Phases (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Services (2021-2034)
12.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Phases (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Services (2021-2034)
12.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Phases (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Services (2021-2034)
12.4.8.3. Market Revenue and Forecast, by End User (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Phases (2021-2034)
12.5.2. Market Revenue and Forecast, by Services (2021-2034)
12.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.5.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Phases (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Services (2021-2034)
12.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Phases (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Services (2021-2034)
12.5.6.3. Market Revenue and Forecast, by End User (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
13.1. Thermos Fischer Scientific, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Sharp Packaging Services
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent Pharma Solutions
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Piramal Pharma Solutions
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. UDG Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. PAREXEL International Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Almac Group Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Movianto GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Patheon, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Biocair International Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample